Dr. Lal Pathlabs Ltd.
Price
Daily candles · NSEWhat the numbers say
- Good return on equity: 3-year ROE 22.9%.
- Comfortable leverage: debt-to-equity of 0.00.
- Sales growth muted at 5.7% over 3 years.
- Profits convert to cash well (CFO/OP 0.78).
- Trades above its industry P/E (31.5 vs 24.3).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Dr. Lal Pathlabs’ arm acquires remaining 30% stake in Centrapath Labs
Pursuant to the aforesaid acquisition, CPL has become a Wholly Owned Subsidiary of PUPL
- Dr. Lal Pathlabs makes further investment in PathLabs Unifiers
The transaction value is not exceeding Rs 30.3 crore
- Dr. Lal PathLabs’ arm completes acquisition of 80% stake in SHL, Ghana
Accordingly, SHL has become a step-down subsidiary of the company
- Dr. Lal PathLabs gets nod to acquire 70% stake in SN Genelab
Post acquisition, SN Gene shall become a Subsidiary of the Company
- Dr. Lal Pathlabs’ arm completes subscription of 30% stake in Neuome Technologies
Pursuant to completion of said subscription, Neuome has now become associate of the company
- Dr. Lal Pathlabs’ arm incorporates subsidiary company in Uzbekistan
The objective of incorporation is to strengthen the group’s presence in Tashkent, Uzbekistan.
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Net Sales | 2,461 | 2,227 | 2,017 | 2,087 | 1,581 |
| Other income | 93 | 69 | 42 | 53 | 51 |
| Total Income | 2,555 | 2,296 | 2,059 | 2,140 | 1,633 |
| Expenditure | 1,766 | 1,617 | 1,527 | 1,527 | 1,145 |
| Operating Profit | 789 | 678 | 532 | 613 | 488 |
| Interest | 22 | 29 | 38 | 30 | 16 |
| Depreciation | 142 | 144 | 150 | 108 | 77 |
| Profit before tax | 625 | 505 | 344 | 475 | 394 |
| Tax | 133 | 143 | 103 | 125 | 98 |
| Net Profit | 492 | 362 | 241 | 350 | 296 |
| EPS (₹) | 58.48 | 43.05 | 28.82 | 41.70 | 35.33 |
| Net margin % | 20.0 | 16.3 | 12.0 | 16.8 | 18.7 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 168 | 84 | 83 | 83 | 83 |
| Reserves | 2,275 | 2,032 | 1,715 | 1,525 | 1,360 |
| Net worth | 2,442 | 2,116 | 1,798 | 1,608 | 1,443 |
| Total sources | 2,689 | 2,311 | 1,990 | 1,913 | 1,843 |
| Net block | 1,224 | 1,135 | 1,194 | 1,305 | 1,369 |
| Capital work in progress | 7 | 3 | 6 | 5 | 15 |
| Investments | 652 | 422 | 165 | 212 | 116 |
| Inventory | 44 | 36 | 37 | 34 | 53 |
| Debtors | 111 | 88 | 77 | 71 | 85 |
| Cash & bank | 910 | 839 | 830 | 665 | 618 |
| Book value (₹) | 145.75 | 253.14 | 215.40 | 192.88 | 173.17 |
Consolidated figures, as filed with the exchanges. Newest year first. Dr. Lal Pathlabs Ltd. had roughly 2× as many shares from FY26 onwards, after a bonus issue or a share split. Book value per share is shown exactly as reported, so FY25 and earlier is struck on the smaller share count and is not comparable with the years after it. The totals above are unaffected.
| Cash Flow · ₹ crore | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| From operations | 569 | 535 | 456 | 447 | 398 |
| From investing | -303 | -24 | -287 | -449 | -212 |
| From financing | -334 | -414 | -283 | 136 | -139 |
| Net change in cash | -68 | 97 | -114 | 134 | 48 |
| Free cash flow | 266 | 511 | 169 | -3 | 186 |
| Closing cash | 293 | 361 | 264 | 378 | 244 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 29.6 | 31.5 | 27.9 | 20.3 | 32.7 |
| ROE % | 22.4 | 25.2 | 21.3 | 15.8 | 26.5 |
| PAT margin % | 18.4 | 20.0 | 16.3 | 12.0 | 16.8 |
| EBIT margin % | 25.0 | 26.3 | 24.0 | 18.9 | 24.2 |
| Debt / equity | 0.00 | 0.00 | 0.05 | 0.15 | 0.24 |
| Current ratio | 3.48 | 3.39 | 2.43 | 2.07 | 1.75 |
| Interest cover | 30.35 | 29.01 | 18.22 | 10.16 | 16.74 |
| Sales growth % | 12.2 | 10.5 | 10.4 | -3.4 | 32.0 |
| Dividend per share (₹) | 20.50 | 24.00 | 24.00 | 12.00 | 12.00 |
| Payout % | 68.0 | 41.2 | 56.0 | 41.9 | 29.0 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Dr. Lal Pathlabs Ltd. (LALPATHLAB) last traded at ₹1,843.70 on the NSE, up +0.41% on the session. Prices on this page are indicative and for information only.
Dr. Lal Pathlabs Ltd. has traded between ₹1,272.60 and ₹2,038.60 over the last 52 weeks on the NSE.
Dr. Lal Pathlabs Ltd. has a market capitalisation of about ₹30,892 crore.
Dr. Lal Pathlabs Ltd. trades at a P/E of 31.5, against an industry P/E of 24.3.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for LALPATHLAB from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Dr. Lal Pathlabs Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in